secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001082554-26-000021
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback
---------------------------------------------------------------------

- Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.
- Tyvaso DPI grew 9% to $330.3M but Nebulized Tyvaso fell 22% to $127.2M; Orenitram up 12%.
- Cost of sales surged 44% to $133.4M, with $26.8M inventory reserve loss on Tyvaso DPI supply agreement.
- Board authorized $2B share repurchase; $1.5B accelerated buyback executed; $500M remaining.
- Positive ADVANCE OUTCOMES and TETON-1 study results; plans to develop ralinepag DPI for PH/fibrosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000021/0001082554-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000021/uthr-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001082554-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer